Literature DB >> 15797628

Breast cancer risk in a large cohort of female antidepressant medication users.

Reina Haque1, Shelley M Enger, Wansu Chen, Diana B Petitti.   

Abstract

Paroxetine in particular has been speculated to increase the risk of breast cancer. The aim of this study was to determine if breast cancer risk is elevated among women who used paroxetine relative to those who used other antidepressants. We conducted a retrospective cohort study of 109,004 female health plan members who used various antidepressants between 1995 and 2000 to evaluate breast cancer risk. The age-adjusted relative risk comparing ever users of paroxetine to those who used other antidepressants was 1.12 (95% CI 0.96-1.31). Women who used paroxetine 2 or more years did not have a greater risk of breast cancer compared to women who used the medication for a shorter period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15797628     DOI: 10.1016/j.canlet.2004.11.003

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  13 in total

Review 1.  Screening pharmaceuticals for possible carcinogenic effects: initial positive results for drugs not previously screened.

Authors:  Gary D Friedman; Natalia Udaltsova; James Chan; Charles P Quesenberry; Laurel A Habel
Journal:  Cancer Causes Control       Date:  2009-12       Impact factor: 2.506

2.  Depression, Antidepressant Use, and Postmenopausal Breast Cancer Risk.

Authors:  Susan B Brown; Susan E Hankinson; Kathleen F Arcaro; Jing Qian; Katherine W Reeves
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2015-11-17       Impact factor: 4.254

Review 3.  Antidepressants and breast and ovarian cancer risk: a review of the literature and researchers' financial associations with industry.

Authors:  Lisa Cosgrove; Ling Shi; David E Creasey; Maria Anaya-McKivergan; Jessica A Myers; Krista F Huybrechts
Journal:  PLoS One       Date:  2011-04-06       Impact factor: 3.240

4.  Antidepressant medication use and breast cancer risk.

Authors:  Karen J Wernli; John M Hampton; Amy Trentham-Dietz; Polly A Newcomb
Journal:  Pharmacoepidemiol Drug Saf       Date:  2009-04       Impact factor: 2.890

Review 5.  Prolactin and breast cancer etiology: an epidemiologic perspective.

Authors:  Shelley S Tworoger; Susan E Hankinson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-02-02       Impact factor: 2.673

6.  Breast cancer recurrence risk in relation to antidepressant use after diagnosis.

Authors:  Jessica Chubak; Diana S M Buist; Denise M Boudreau; Mary Anne Rossing; Thomas Lumley; Noel S Weiss
Journal:  Breast Cancer Res Treat       Date:  2007-12-06       Impact factor: 4.872

7.  A population-based case-control study of Selective Serotonin Reuptake Inhibitors (SSRIs) and breast cancer: the impact of duration of use, cumulative dose and latency.

Authors:  J E Ashbury; L E Lévesque; P A Beck; K J Aronson
Journal:  BMC Med       Date:  2010-12-22       Impact factor: 8.775

8.  Selective Serotonin Reuptake Inhibitor (SSRI) Antidepressants, Prolactin and Breast Cancer.

Authors:  Janet E Ashbury; Linda E Lévesque; Patricia A Beck; Kristan J Aronson
Journal:  Front Oncol       Date:  2012-12-05       Impact factor: 6.244

9.  Medication use and the risk of breast cancer.

Authors:  Scott Davis; Dana K Mirick
Journal:  Eur J Epidemiol       Date:  2007-05-09       Impact factor: 12.434

10.  Use of antidepressant medications in relation to the incidence of breast cancer.

Authors:  D Fulton-Kehoe; M A Rossing; C Rutter; M T Mandelson; N S Weiss
Journal:  Br J Cancer       Date:  2006-04-10       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.